Caliskan Ahmet, Kirisci Ozlem, Ozkaya Esra, Ozden Sevinc, Tumer Seray, Caglar Serkan, Guler Selma Ates, Senol Hande
Department of Medical Microbiology, Necip Fazil City Hospital, Kahramanmaras, Turkey.
Department of Medical Biohemistry, Necip Fazıl City Hospital, Kahramanmaras, Turkey.
Hepat Mon. 2015 Apr 25;15(4):e25142. doi: 10.5812/hepatmon.15(4)2015.25142. eCollection 2015 Apr.
The hepatitis C virus (HCV) has six major genotypes and more than 100 subtypes, and the determination of the responsible genotype, collection of epidemiological data, tailoring antiviral therapy, and prediction of prognosis have an important place in disease management.
The aim of the present study was to determine the distribution of HCV genotypes across geographic regions and compare these data with those obtained from other geographic locations.
The HCV genotypes were identified in HCV RNA positive blood samples, obtained from different centers. The HCV genotype was determined using molecular methods [Real-Time Polymerase Chain Reaction (RT-PCR)] in 313 patients, who were found to be positive for HCV RNA. The presence of HCV RNA was investigated using the RT-PCR method in serum samples delivered to the Microbiology Laboratory at Kahramanmaras Necip Fazıl City Hospital, Kahramanmaras, Turkey, from the centers located in Kahramanmaras City center and peripheral districts of the province, between March 2010 and August 2014. The HCV genotype analysis was performed in HCV RNA positive samples, using RT-PCR reagents kit. Urine samples from the patients were tested for amphetamine with an Amphetamines II (AMPS2) kit, cocaine was tested with a Cocaine II (COC2) kit, opiates were tested with an Opiates II (OPI2) kit, and cannabinoids were tested with a Cannabinoids II (THC2) kit in Roche/Hitachi Cobas c501 device.
The blood samples collected from 313 patients were included in the study. Of these patients, 212 (67.7%) were male and 101 (32.3%) were female. The mean age of the patients was 41.29 ± 20.32 years. In terms of HCV genotype distribution, 162 patients (51.7%) had genotype 1, 144 patients (46%) had genotype 3, four patients (1.3%) had genotype 2, and three patients (1%) had genotype 4. The results of urine drug tests were available in only 65 patients (20.2%). Of these, 61 (93.8%) patients had HCV genotype 3.
In conclusion, the prevalence of HCV genotype 1 was 51.7%, which was lower than the rates reported in other studies in Turkey, while the prevalence of HCV genotype 3 was 46%, which was remarkably higher than the reported Turkish data. In addition, the prevalence rate for genotype 3 reported in the present study is the highest that has ever been reported in the literature.
丙型肝炎病毒（HCV）有六种主要基因型和100多种亚型，确定相关基因型、收集流行病学数据、制定抗病毒治疗方案以及预测预后在疾病管理中具有重要地位。
本研究旨在确定HCV基因型在不同地理区域的分布，并将这些数据与其他地理位置的数据进行比较。
从不同中心获取HCV RNA阳性血样，鉴定HCV基因型。采用分子方法[实时聚合酶链反应（RT-PCR）]对313例HCV RNA检测呈阳性的患者进行HCV基因型测定。2010年3月至2014年8月期间，将来自土耳其加济安泰普市纳齐普·法齐尔市立医院微生物实验室的血清样本，运用RT-PCR方法检测HCV RNA的存在情况，这些样本来自加济安泰普市中心及该省周边地区的各个中心。使用RT-PCR试剂试剂盒对HCV RNA阳性样本进行HCV基因型分析。在罗氏/日立Cobas c501仪器上，使用安非他明II（AMPS2）试剂盒检测患者尿液样本中的安非他明，使用可卡因II（COC2）试剂盒检测可卡因，使用阿片类物质II（OPI2）试剂盒检测阿片类物质，使用大麻素II（THC2）试剂盒检测大麻素。
本研究纳入了从313例患者采集的血样。其中，男性212例（67.7%），女性101例（32.3%）。患者的平均年龄为41.29±20.32岁。就HCV基因型分布而言，162例患者（51.7%）为基因型1，144例患者（46%）为基因型3，4例患者（1.3%）为基因型2，3例患者（1%）为基因型4。仅65例患者（20.2%）有尿液药物检测结果。其中，61例（93.8%）患者为HCV基因型3。
总之，HCV基因型1的患病率为51.7%，低于土耳其其他研究报告的患病率，而HCV基因型3的患病率为46%，显著高于所报告的土耳其数据。此外，本研究报告的基因型3患病率是文献中报道过的最高值。
